论文部分内容阅读
目的 :评估胰岛素增敏剂吡格列酮对 2型糖尿病 (T2 DM)患者血浆内皮素 (ET)水平的影响。方法 :4 8名伴有轻度血管并发症的 T2 DM患者 ,随机、双盲分成吡格列酮组 (A组 2 4例 )、安慰剂组 (B组 2 4例 ) ,2 0名健康者作为对照组 (C组 ) ,采用放免法测定予吡格列酮治疗 3个月前后空腹血浆 ET及血清胰岛素水平 (FIns)。 结果 :(1)治疗前 A、B两组的空腹血浆 ET水平均明显高于 C组 (P<0 .0 1) ;(2 ) A、B两组的空腹血浆 ET水平与胰岛素成正相关 (r A=0 .6 35 1,r B=0 .6 4 87,P<0 .0 1) ;(3)治疗后 A组空腹血浆 ET、FIns、空腹血糖 (FBG)、糖化血红蛋白 (Hb A1 c)、甘油三酯 (TG)均有降低 (P<0 .0 1)。 (4) A、B两组不良反应的发生例数均为 8例。结论 :(1)伴有轻度血管并发症 T2 DM患者空腹血浆 ET水平升高 ;(2 )吡格列酮可降低 T2 DM患者空腹血浆 ET水平 ,有益于改善糖尿病血管并发症 ;(3)吡格列酮是治疗 2型糖尿病患者安全有效的药物
Objective: To evaluate the effect of insulin sensitizer pioglitazone on plasma endothelin (ET) in type 2 diabetes mellitus (T2DM). Methods: Forty-eight T2DM patients with mild vascular complications were randomly divided into two groups: pioglitazone group (24 cases in group A), placebo group (24 cases in group B) and 20 healthy controls Group C (group C). Fasting plasma ET and serum insulin levels (FIns) were measured by radioimmunoassay three days before pioglitazone treatment. Results: (1) Fasting plasma ET levels in groups A and B before treatment were significantly higher than those in group C (P <0.01). (2) Fasting plasma ET levels in groups A and B were positively correlated with insulin (3) After treatment, the fasting plasma ET, FIns, fasting blood glucose (FBG), glycosylated hemoglobin (Hb A1) in group A were significantly lower than those in group A (P0.05) c) and triglyceride (TG) decreased (P <0.01). (4) A and B two groups of adverse reactions occurred in the number of cases were 8 cases. (2) Pioglitazone can reduce the level of fasting plasma ET in T2DM patients and improve the diabetic vascular complications; (3) Pioglitazone is the treatment of T2DM patients with T2DM; Safe and effective drug for type 2 diabetes